Inhibition of the mammalian target of rapamycin and the induction of cell cycle arrest in mantle cell lymphoma cells

被引：0

作者：

Hipp, Susanne ^{[1
]}

Ringshausen, Ingo ^{[1
]}

Oelsner, Madlene ^{[1
]}

Bogner, Christian ^{[1
]}

Peschel, Christian ^{[1
]}

Decker, Thomas ^{[2
]}

机构：

[1] Tech Univ Munich, Dept Med 3, Ismaninger Str 15, D-81675 Munich, Germany

[2] Schwerpunktpraxis Tumortherapie, Weingarten, Germany

来源：

HAEMATOLOGICA | 2005年 / 90卷 / 10期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Mammalian target of rapamycin (mTOR) inhibitors represent a new class of potential anti-cancer agents. The mTOR inhibitor, rapamycin, inhibited proliferation in three mantle cell lymphoma (MCL) cell lines and reduced cyclin D3 expression while cyclin D1 levels remained unchanged. This finding was confirmed in cells from a MCL patient.

引用

页码：1433 / 1434

页数：2

共 11 条

[1] Molecular basis of mantle cell lymphoma [J].

Bertoni, F ;

Zucca, E ;

Cotter, FE .

BRITISH JOURNAL OF HAEMATOLOGY, 2004, 124 (02) :130-140

[2] The TOR pathway: A target for cancer therapy [J].

Bjornsti, MA ;

Houghton, PJ .

NATURE REVIEWS CANCER, 2004, 4 (05) :335-348

[3] Rapamycin inhibits the growth and metastatic progression of non-small cell lung cancer [J].

Boffa, DJ ;

Luan, FL ;

Thomas, D ;

Yang, H ;

Sharma, VK ;

Lagman, M ;

Suthanthiran, M .

CLINICAL CANCER RESEARCH, 2004, 10 (01) :293-300

[4] Inhibition of the proteasome induces cell cycle arrest and apoptosis in mantle cell lymphoma cells [J].

Bogner, C ;

Ringshausen, I ;

Schneller, F ;

Fend, F ;

Quintanilla-Martinez, L ;

Häcker, G ;

Goetze, K ;

Oostendorp, R ;

Peschel, C ;

Decker, T .

BRITISH JOURNAL OF HAEMATOLOGY, 2003, 122 (02) :260-268

[5] Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin [J].

Decker, T ;

Hipp, S ;

Ringshausen, I ;

Bogner, C ;

Oelsner, M ;

Schneller, F ;

Peschel, C .

BLOOD, 2003, 101 (01) :278-285

[6] High-dose chemoradiotherapy and anti-B-cell monoclonal antibody purged autologous bone marrow transplantation in mantle-cell lymphoma: No evidence for long-term remission [J].

Freedman, AS ;

Neuberg, D ;

Gribben, JG ;

Mauch, P ;

Soiffer, RJ ;

Fisher, DC ;

Anderson, KC ;

Andersen, N ;

Schlossman, R ;

Kroon, M ;

Ritz, J ;

Aster, J ;

Nadler, LM .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (01) :13-18

[7] Sirolimus (rapamycin)-based therapy in human renal transplantation -: Similar efficacy and different toxicity compared with cyclosporine [J].

Groth, CG ;

Bäckman, L ;

Morales, JM ;

Calne, R ;

Kreis, H ;

Lang, P ;

Touraine, JL ;

Claesson, K ;

Campistol, JM ;

Durand, D ;

Wramner, L ;

Brattström, C ;

Charpentier, B .

TRANSPLANTATION, 1999, 67 (07) :1036-1042

[8] Evidence for cyclin D3 as a novel target of rapamycin in human T lymphocytes [J].

Hleb, M ;

Murphy, S ;

Wagner, EF ;

Hanna, NN ;

Sharma, N ;

Park, J ;

Li, XC ;

Strom, TB ;

Padbury, JF ;

Tseng, YT ;

Sharma, S .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (30) :31948-31955

[9] Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: Molecular complete responses are not predictive of progression-free survival [J].

Howard, OM ;

Gribben, JG ;

Neuberg, DS ;

Grossbard, M ;

Poor, C ;

Janicek, MJ ;

Shipp, MA .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (05) :1288-1294

[10] Targeting mTOR signaling for cancer therapy [J].

Huang, S ;

Houghton, PJ .

CURRENT OPINION IN PHARMACOLOGY, 2003, 3 (04) :371-377

← 1 2 →